Vuong Trieu - 22 Jan 2026 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Reporting relationship: CHAIRMAN AND CEO, Director, 10%+ Owner
Issuer ticker: OTLC
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 17:15:27 UTC
Prior SEC filing: 19 Nov 2025
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Vuong Trieu

Key filing fact

Vuong Trieu filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 26 Jan 2026.

Key facts

This page summarizes Vuong Trieu's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2026, 17:15.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001587074 Primary reporting owner

Trieu Vuong

Relationship: CHAIRMAN AND CEO, Director, 10%+ Owner
Address: 29397 AGOURA RD SUITE 107, AGOURA HILLS
Signature: /s/ Vuong Trieu
Signature date: 26 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLC transaction Derivative

Series A Convertible Preferred Stock

Award

Transaction value: $0
Shares: +4,426
Change %: +109%
Price: $0.000000
Shares after: 8,491
Date: 22 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,426,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.

Footnote F2

The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026.